Zahlten-Hinguranage A, Goldschmidt H, Cremer F W, Egerer G, Moehler T, Witte D, Bernd L, Sabo D, Zeifang F
Department of Orthopedic Surgery, University of Heidelberg, Heidelberg, Germany.
Br J Cancer. 2006 Oct 9;95(7):782-7. doi: 10.1038/sj.bjc.6603329. Epub 2006 Sep 12.
We investigated whether preoperative levels of serum C-reactive protein (CRP) and its correlation with tumour clinicopathological findings adds prognostic information beyond the time of diagnosis in patients with myeloma bone disease (MM) to facilitate the surgical decision-making process. Six hundred and fifty-eight myeloma patients were evaluated retrospectively for surgery. Clinicopathological variables of patients who underwent surgery (n=71) were compared between patients with preoperative CRP>or=6 mg l-1 and those with CRP<6 mg l-1. Univariate and multivariate analyses were performed to identify prognostic factors after surgery. Patients with an increase of CRP prior to surgery showed inferior survival compared to patients with normal levels. Patients with normal CRP levels at diagnosis but elevations prior to surgery do seem to have a similar unfavourable overall survival (OS) than patients with an increase both, at diagnosis and at surgery. Conversely, patients with normal CRP levels prior to surgery still have the best OS, irrespective of their basic values. Multivariate analysis revealed preoperative CRP levels above 6 mg l-1 Lactate dehydrogenase (LDH) above normal, and osteolyses in long weight bearing bones as independent predictors of survival. These findings suggest that in patients with MM serum levels of CRP increase during disease activity and might be significantly correlated with specific disease characteristics including adverse prognostic features such as osteolyses in long weight bearing bones. Thus, preoperative elevated CRP serum levels might be considered as independent predictor of prognosis and could provide additional prognostic information for the risk stratification before surgical treatment in patients with myeloma bone disease.
我们研究了骨髓瘤骨病(MM)患者术前血清C反应蛋白(CRP)水平及其与肿瘤临床病理结果的相关性,是否能在诊断时间之外提供预后信息,以促进手术决策过程。对658例骨髓瘤患者进行了回顾性手术评估。比较了术前CRP≥6 mg/L和CRP<6 mg/L的手术患者(n=71)的临床病理变量。进行单因素和多因素分析以确定术后的预后因素。术前CRP升高的患者与CRP正常的患者相比,生存率较低。诊断时CRP水平正常但术前升高的患者,其总生存期(OS)似乎与诊断和手术时均升高的患者相似。相反,术前CRP水平正常的患者无论其基础值如何,OS仍然最佳。多因素分析显示,术前CRP水平高于6 mg/L、乳酸脱氢酶(LDH)高于正常水平以及长承重骨出现骨质溶解是生存的独立预测因素。这些发现表明,在MM患者中,CRP血清水平在疾病活动期间升高,可能与特定疾病特征显著相关,包括长承重骨骨质溶解等不良预后特征。因此,术前CRP血清水平升高可被视为独立的预后预测因素,并可为骨髓瘤骨病患者手术治疗前的风险分层提供额外的预后信息。